Although its mutation frequency is relatively low in AML (less than 10% of de novo AML cases) compared to solid tumors (more than50% of cases), the function of TP53 in AML could not be ignored, as dysfunctional wild-type (WT) TP53 appears in various AML entities, implying a more attention to be paid (122). The gene discussed is TP53; the disease is acute myeloid leukemia.